Tirzepatide vs Semaglutide 2026: Which GLP-1 Wins for Weight Loss?
Reviewed against the SURMOUNT-5 head-to-head trial (NEJM, May 2025), SURMOUNT-1 (NEJM, 2022), STEP-1 (NEJM, 2021), and current FDA labeling.
Tirzepatide produced more weight loss head-to-head. Semaglutide is still effective. Cost and tolerance are the real swing factors.
The honest answer: for most patients starting from scratch, tirzepatide (Mounjaro / Zepbound) is the stronger molecule based on the May 2025 head-to-head SURMOUNT-5 trial. But semaglutide (Wegovy / Ozempic) still produces clinically significant weight loss, costs less in compounded form, and is the right choice if you tolerate it well or have insurance coverage that favors it.
Head-to-Head At A Glance
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | Dual GLP-1 + GIP receptor agonist | GLP-1 receptor agonist |
| Avg weight loss (SURMOUNT-5, 72 weeks) | −20.2% | −13.7% |
| Branded names | Mounjaro (T2D), Zepbound (weight) | Ozempic (T2D), Wegovy (weight), Rybelsus (oral T2D) |
| Dosing frequency | Once weekly injection | Once weekly injection (or daily oral for Rybelsus) |
| Half-life | ~5 days | ~7 days |
| Top GI side effect (clinical trials) | Nausea 24–33% | Nausea ~44% (at 2.4 mg) |
| Branded list price (May 2026 cash) | Zepbound ~$1,086/mo | Wegovy ~$1,349/mo |
| Compounded telehealth price (May 2026) | $249–$399/mo | $179–$314/mo |
| Discontinuation in trials (AEs) | 4.3–7.1% | 4.5–5.6% |
Sources: SURMOUNT-5 (NEJM, May 2025), SURMOUNT-1 (NEJM, 2022), STEP-1 (NEJM, 2021), FDA labels (May 2026), and current telehealth provider pricing as of May 2026. See full citations in each section below.
How They Work: One Hormone vs Two
Both drugs work by mimicking gut hormones that are naturally released when you eat. These hormones tell your pancreas to release insulin and tell your brain you are full. The difference is the number of receptors each drug targets.
Tirzepatide — dual agonist
Activates two gut-hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The GIP arm amplifies post-meal insulin release, suppresses appetite further, and may improve fat metabolism. This is the mechanistic explanation for tirzepatide’s edge in head-to-head data.
Semaglutide — single agonist
Activates only the GLP-1 receptor. Effective on its own — semaglutide produced 14.9% mean weight loss in the STEP-1 trial vs 2.4% for placebo — but does not match tirzepatide head-to-head because it lacks the second hormone pathway.
Sources: NEJM SURMOUNT-5 pharmacology; FDA labels for Mounjaro, Zepbound, Wegovy, and Ozempic (current May 2026).
The Trial Data: SURMOUNT-5 Settled It
For years, the comparison was indirect — tirzepatide and semaglutide had been tested against placebo, not each other. That changed in May 2025 when the New England Journal of Medicine published SURMOUNT-5: a direct head-to-head trial of both drugs at maximum tolerated doses for 72 weeks.
SURMOUNT-5
Tirzepatide vs Semaglutide (head-to-head)
SURMOUNT-1
Tirzepatide (placebo-controlled)
STEP-1
Semaglutide (placebo-controlled)
What 6.5 percentage points actually means
For someone starting at 220 lb (100 kg): tirzepatide’s 20.2% mean loss is approximately 44 lb. Semaglutide’s 13.7% mean loss is approximately 30 lb. That is roughly 14 lb of additional loss on tirzepatide over 72 weeks — at the same trial endpoint, with the same protocol, in the same patient population. The difference is statistically significant (P<0.001).
Side Effects Compared
Both drugs share the same dominant side-effect category: GI symptoms from the gut-hormone receptor activation. The pattern that emerged across trials and on forums is that semaglutide drives more nausea and vomiting, while tirzepatide drives slightly more diarrhea and constipation. Slow titration is the single biggest factor in tolerability for either drug.
| Side Effect | Tirzepatide (SURMOUNT) | Semaglutide 2.4mg (STEP) |
|---|---|---|
| Nausea | 24–33% | ~44% |
| Diarrhea | 19–23% | ~30% |
| Constipation | 11–17% | ~24% |
| Vomiting | 8–13% | ~24% |
| Abdominal pain | 9–10% | Similar range |
| Discontinuation due to AEs (trials) | 4.3–7.1% | 4.5–5.6% |
Why titration is the single biggest factor
The standard tirzepatide titration is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg with increases every 4 weeks. Semaglutide titrates 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg on the same 4-week schedule. Real-world discontinuation rates run 15–25% in the first 6–12 months — much higher than the trial numbers — and the most common reason cited on r/Semaglutide and r/Tirzepatide is being titrated up too fast.
If a telehealth provider tries to escalate your dose every 2 weeks instead of every 4, push back. The 4-week schedule is in the FDA label for a reason.
Cost: Branded, Compounded, and Insurance
Pricing has shifted significantly in 2026 because of two events: Eli Lilly and Novo Nordisk both expanded cash-pay savings cards (driving branded prices down for some patients), and the FDA proposed on April 30, 2026 to remove tirzepatide and semaglutide from the 503B compounding bulks list. That second event is reshaping the compounded market — see the box below.
- Mounjaro (T2D approval) — ~$1,086/mo cash list
- Zepbound (weight-loss approval) — ~$1,086/mo cash list
- LillyDirect savings card — drops cash to $199–$449/mo for qualifying patients (expires 12/31/2026)
- Compounded tirzepatide via telehealth — $249–$399/mo (May 2026, post-shortage)
- Insurance — Zepbound covered by most commercial plans when BMI + comorbidity criteria met; OOP typically $25–$150/mo
- Wegovy (weight-loss approval) — ~$1,349/mo cash list
- Ozempic (T2D approval) — ~$1,028/mo cash list
- Rybelsus (oral semaglutide, T2D) — ~$1,028/30-day
- NovoCare savings card — comparable mid-range cash discount (Novo announced 50% list-price cut to $675 effective Jan 2027)
- Compounded semaglutide via telehealth — $179–$314/mo (May 2026)
- Insurance — Wegovy covered by most commercial plans when criteria met; Medicare still does not cover for weight loss alone
Compounded GLP-1 status changed in May 2026
The FDA officially declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. As of May 2026, neither drug is on the FDA shortage list. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — effectively making large-scale 503B compounding illegal. Only 503A patient-specific compounding (one prescription, one patient, one batch) remains legal. Compounded prices have risen post-enforcement.
If you are currently on compounded GLP-1, talk to your prescriber about transition options. If you are starting fresh, factor in that your compounded pharmacy could be forced to stop dispensing during your treatment. Read our compounded GLP-1 survival guide for the full picture.
Sources: Manufacturer pricing pages and GoodRx/TrumpRx data (May 2026); CMS Medicare GLP-1 Bridge program; FDA Drug Shortage List; FDA April 30, 2026 proposed rule on 503B bulks.
What Real Users Say
The best signal for what either drug is like in practice comes from people taking them. The quotes below are pulled verbatim from r/Tirzepatide, r/Semaglutide, and r/zepbound_support — public threads, public handles, with attribution. The pattern that recurs: many patients who plateau on semaglutide find renewed loss on tirzepatide, and a meaningful subset find tirzepatide easier on the GI tract too.
“Tirzepatide is hands down better for me — lost 25% vs 12% on Wegovy and way less nausea.”
Larger loss + better tolerability is a recurring theme on r/Tirzepatide.
“Semaglutide worked but plateaued hard at month 4; switched to tirz and broke through immediately.”
The plateau-then-switch pattern is the most common reason real users report changing drugs.
“Switched from Wegovy 2.4 to Zepbound 7.5 and finally losing again — side effects actually better.”
For some patients, tirzepatide is both more effective AND better tolerated than semaglutide.
Quotes are reproduced verbatim from public Reddit posts. Individual results vary significantly. These are not endorsements and not medical advice. Consult a licensed prescriber before making any treatment decisions.
Which One Is Right For You?
Use this decision framework. Most patients land in one of four buckets.
Pick tirzepatide (Zepbound or Mounjaro) if…
- You are starting GLP-1 therapy fresh and want the strongest molecule on average
- You have plateaued on semaglutide and need a stronger second option
- Your insurance covers Zepbound for weight loss
- You experienced severe nausea on semaglutide and want a lower-nausea profile
Pick semaglutide (Wegovy or Ozempic) if…
- You are cost-sensitive — compounded semaglutide is meaningfully cheaper than compounded tirzepatide
- Your insurance covers Wegovy or Ozempic but not Zepbound
- You are on Ozempic for type-2 diabetes already and stable
- You experienced GI distress (diarrhea/constipation) on tirzepatide and want a different profile
This decision tree is informational. Your prescriber will factor in additional variables (kidney function, gallbladder history, family history of medullary thyroid cancer, current medications, pregnancy plans, etc.) that can shift the recommendation.
Where to Get Tirzepatide or Semaglutide via Telehealth
The six telehealth providers below all prescribe both drugs (compounded, branded, or both). Pricing verified May 2026. Click any provider to see current pricing and start a consultation.
Telehealth Providers Offering Tirzepatide or Semaglutide
Pricing accurate as of May 2026. Click a provider to see current pricing and start a consultation. We may earn a commission — at no extra cost to you. See our affiliate disclosure.
| Provider | Monthly Price | Rating | Action |
|---|---|---|---|
SkinnyRxBest Overall 503A compounded GLP-1 specialistCompounded Tirzepatide + Semaglutide (503A pharmacy) | $199–$399 | ★★★★★4.9 | View Best Offer |
TrimRx Online weight loss program with GLP-1 medicationGLP-1 weight loss program (catalog VERIFY) | From $179/mo | ★★★★☆4.5 | View Best Offer |
MEDViEditor’s Pick Reliable mid-tier compounded GLP-1Compounded Tirzepatide + Semaglutide | $179–$299 | ★★★★☆4.6 | View Best Offer |
DirectMedsBest for Sublingual Sublingual + injectable compounded GLP-1Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon | $179–$399 | ★★★★☆4.5 | View Best Offer |
Ivim HealthBest for Microdosing 360 wellness — branded + compounded + microdosing GLP-1Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill | From $75/mo + $74.99 program fee | ★★★★☆4.7 | View Best Offer |
Eden HealthBest Value Branded + compounded with intro pricingCompounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy | $149 intro / $229–$249 ongoing | ★★★★☆4.7 | View Best Offer |
Sprout Health PENDING — URL not yet confirmedVERIFY | VERIFY | ☆☆☆☆☆0.0 | View Best Offer |
Elevate Health 3-month tirzepatide starter programCompounded Tirzepatide (2.5–15 mg/wk titration), Compounded Semaglutide | $299/mo or $897/3-mo bundle | ★★★★☆4.4 | View Best Offer |
OrderlyMeds Personalized GLP-1 + $3,700 value bundleCompounded Tirzepatide + Semaglutide, Wegovy, Zepbound | $149–$299 compounded, $1,498–$1,839 branded | ★★★★☆4.5 | View Best Offer |
GobyMeds Compounded GLP-1 with B12/NAD+ stack add-onsCompounded Sema + Tirz with B12/B6/NAD+/glycine combos, Wegovy, Zepbound, Sermorelin, NAD+ | From $99/mo (compounded sema) | ★★★★☆4.6 | View Best Offer |
Ro Largest US telehealth platformBranded (Wegovy, Zepbound) + select compounded | $149/mo + meds | ★★★★☆4.6 | View Best Offer |
Calibrate Coaching-led metabolic programBranded GLP-1s + 1:1 coaching + labs | $199/mo (3-month minimum) | ★★★★☆4.3 | View Best Offer |
Found Insurance-first weight-care platformBranded (insurance-billed) + compounded | ~$129/mo + meds | ★★★★☆4.2 | View Best Offer |
EmbodyBest Overall Flat $299/mo refills + GLP-1 gum (needle-free)Compounded Semaglutide + Tirzepatide (injectable + GLP-1 gum) | $149 first month / $299 flat refills | ★★★★★4.7 | View Best Offer |
Gala HealthBest for 3-Month Bundles All-inclusive 3-month GLP-1 bundles from $179–$199/moCompounded Semaglutide or Tirzepatide (GLP-1/GIP) | $179–$199/mo (3-month plan) | ★★★★☆4.5 | View Best Offer |
Care Bare RxBest Multi-Vertical Weight loss + hair + sexual health + NAD+ — discreet multi-careCompounded Semaglutide + Tirzepatide (oral + injectable) + hair + sexual health + NAD+ | From $199/mo (weight loss) | ★★★★☆4.4 | View Best Offer |
System LabsBest Value Lowest GLP-1 entry ($179/mo) + longevity stack — NAD+, B-12, sermorelinCompounded GLP-1 + NAD+ + B-12 + Sermorelin (oral + injectable) | GLP-1 $179/mo (lowest entry) | ★★★★☆4.5 | View Best Offer |
Strut Health No-video telehealth — GLP-1, hair, skin, ED + 2-day shippingCompounded Semaglutide + Tirzepatide, Hair Loss, Oral Sermorelin, Skin Care, ED | Oral Semaglutide from $99/mo, Oral Tirzepatide from $199/mo | ★★★★☆4.6 | View Best Offer |
TMatesBest Overall $158-$249/mo semaglutide, $167-$297/mo tirzepatide — same price all dosesCompounded Semaglutide + Tirzepatide (GLP-1), NAD+, TRT, ED, Skin Care, Hair Loss | Semaglutide $158-$249/mo, Tirzepatide $167-$297/mo (1-12 mo plans) | ★★★★☆4.7 | View Best Offer |
Pricing and availability current as of May 2026. We earn a commission if you sign up through our links — at no additional cost to you. See our methodology for how we evaluate providers.
Frequently Asked Questions
Which is better for weight loss, tirzepatide or semaglutide?+
Tirzepatide produced more weight loss in the SURMOUNT-5 head-to-head trial published in NEJM (May 2025): -20.2% vs -13.7% at 72 weeks (P<0.001). Tirzepatide was also superior on waist circumference and on the proportion of patients achieving 10%, 15%, 20%, and 25% weight loss thresholds. Both drugs are FDA-approved and effective; tirzepatide is the stronger molecule on average. Individual response varies — some patients tolerate semaglutide better.
Is tirzepatide stronger than semaglutide?+
Yes, mechanistically. Tirzepatide is a dual GLP-1 + GIP receptor agonist, meaning it activates two gut-hormone pathways instead of one. Semaglutide only activates the GLP-1 receptor. The added GIP receptor activity amplifies post-meal insulin release, further suppresses appetite, and may improve fat metabolism. This dual-receptor design explains the 5–7 percentage-point greater weight loss seen in head-to-head data.
How much more weight do you lose on tirzepatide vs semaglutide?+
In the SURMOUNT-5 trial (NEJM, May 2025), tirzepatide produced 6.5 percentage points more weight loss than semaglutide at the same 72-week endpoint: -20.2% vs -13.7%. For someone starting at 220 lb, that is approximately 14 lb more loss on tirzepatide. The gap was statistically significant (P<0.001). Real-world results vary based on titration, adherence, diet, and individual response.
What are the side effects of tirzepatide vs semaglutide?+
Both have GI-dominant side effects from clinical trials. Tirzepatide top 5: nausea (24-33%), diarrhea (19-23%), constipation (11-17%), vomiting (8-13%), abdominal pain (9-10%). Semaglutide top 5 at the 2.4 mg weight-loss dose: nausea (~44%), diarrhea (~30%), vomiting (~24%), constipation (~24%), abdominal pain. Real-world pattern: semaglutide tends to cause more nausea and vomiting; tirzepatide tends to cause slightly more diarrhea and constipation. Both improve significantly with slow dose titration.
How much does tirzepatide cost compared to semaglutide?+
Branded cash pricing as of May 2026: Mounjaro and Zepbound (tirzepatide) approximately $1,086/month; Wegovy (semaglutide) approximately $1,349/month; Ozempic (semaglutide) approximately $1,028/month. Manufacturer savings cards from Eli Lilly and Novo Nordisk drop cash prices to roughly $199-$449/month for qualifying patients. Compounded telehealth pricing as of May 2026: compounded tirzepatide $249-$399/month; compounded semaglutide $179-$314/month. Note: compounded versions face regulatory uncertainty after the FDA April 30, 2026 proposal to exclude both drugs from the 503B bulks list.
Can I switch from semaglutide to tirzepatide?+
Yes, and many patients do. Anecdotally on r/Tirzepatide and r/Semaglutide, the most common reason for switching is plateaued weight loss on semaglutide. Standard practice is to discontinue semaglutide for one weekly cycle, then start tirzepatide at 2.5 mg and titrate upward every 4 weeks. Always make this decision with a licensed prescriber — switching directly without a wash-out can amplify GI side effects.
Related Comparison Guides
Editorial note: This page is reviewed against primary clinical-trial sources (NEJM publications) and current FDA labeling. Pricing data was verified May 1, 2026 from manufacturer pricing pages and from each telehealth provider’s site. Reddit quotes are reproduced verbatim from public posts with attribution. Affiliate program details (commission rates, cookie durations, network) reflect what’s publicly visible on affiliate networks including OfferVault, AffiliArt, and DYNU as of May 2026 — direct verification pending program approvals.
Not medical advice. Always consult a licensed prescriber before starting, switching, or stopping any GLP-1 medication.
Related Guides
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Related Guides
Continue your research with these related independent reviews.